ArticleCurrent osteoporosis reports2013
Evaluation and management of the premenopausal woman with low BMD.
Article in Current osteoporosis reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Pathway-Level Reorganization of Genetic Signals Associated with Low Bone Mineral Density Across the Menopausal Transition.International journal of molecular sciences · 2026Article
- Risk factor of osteoporosis in systemic lupus erythematosus patients: a cross-sectional study in a tertiary hospital in Indonesia.Lupus science & medicine · 2026Article
- Endometriosis-associated bone loss: re-evaluating the potential role of systemic inflammation and hypoestrogenic therapies.Frontiers in global women's health · 2026Review
- Impact of Endocrine Therapy on Osteoporosis Risk in Women with Breast Cancer Across Different Hormonal Stages: A Review.Current oncology (Toronto, Ont.) · 2025Review
- Risk factors for glucocorticoid induced osteoporosis in young adults.Frontiers in endocrinology · 2025Article
- Two-year follow-up study (PRIMROSE 3) to assess bone mineral density in subjects with uterine fibroids completing the PRIMROSE 1 and PRIMROSE 2 linzagolix trials.Human reproduction open · 2025Article
- Enhanced Osteoporosis Detection Using Artificial Intelligence: A Deep Learning Approach to Panoramic Radiographs with an Emphasis on the Mental Foramen.Medical sciences (Basel, Switzerland) · 2024Article
- Dietary glycemic and insulin indices with the risk of osteoporosis: results from the Iranian teachers cohort study.Frontiers in nutrition · 2024Article
- Integrating real-world data and modeling to project changes in femoral neck bone mineral density and fracture risk in premenopausal women.Clinical and translational science · 2021Article
- Vertebral fracture risk in glucocorticoid-induced osteoporosis: the role of hypogonadism and corticosteroid boluses.RMD open · 2020Article
- Vertebral Imaging in the Diagnosis of Osteoporosis: a Clinician's Perspective.Current osteoporosis reports · 2017Review
- Premenopausal Osteoporosis.Endocrinology and metabolism clinics of North America · 2017Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
Interpretation of bone mineral density (BMD) results in premenopausal women is particularly challenging, since the relationship between BMD and fracture risk is not the same as for postmenopausal women. In most cases, Z scores rather than T scores should be used to define "low BMD" in premenopausal women. The finding of low BMD in a premenopausal woman should prompt thorough evaluation for secondary causes of bone loss. If a secondary cause is found, management should focus on treatment of this condition. In a few cases where the secondary cause cannot be eliminated, treatment with a bone active agent to prevent bone loss should be considered. In women with no fractures and no known secondary cause, low BMD is associated with microarchitectural defects similar to young women with fractures; however, no longitudinal data are available to allow use of BMD to predict fracture risk. BMD is likely to be stable in these women with isolated low BMD, and pharmacologic therapy is rarely necessary. Assessment of markers of bone turnover and follow-up bone density measurements can help to identify those with an ongoing process of bone loss that may indicate a higher risk for fracture, and possible need for pharmacologic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.